These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20375984)

  • 1. Efficacy and safety of SBR759, a new iron-based phosphate binder.
    Block GA; Brillhart SL; Persky MS; Amer A; Slade AJ
    Kidney Int; 2010 May; 77(10):897-903. PubMed ID: 20375984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
    Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
    Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    J Ren Nutr; 2014 Jul; 24(4):261-7. PubMed ID: 24836401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
    Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
    Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope (58)Fe.
    Gschwind HP; Schmid DG; von Blanckenburg F; Oelze M; van Zuilen K; Slade AJ; Stitah S; Kaufmann D; Swart P
    Metallomics; 2014 Nov; 6(11):2062-71. PubMed ID: 25017110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ironing out the phosphorus problem.
    Zaritsky JJ; Salusky IB
    Kidney Int; 2010 May; 77(10):845-7. PubMed ID: 20431575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
    Spiegel DM; Farmer B; Smits G; Chonchol M
    J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
    Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J;
    Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
    Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP;
    Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF;
    Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-based phosphate binders--a new element in management of hyperphosphatemia.
    Pai AB; Jang SM; Wegrzyn N
    Expert Opin Drug Metab Toxicol; 2016; 12(1):115-27. PubMed ID: 26572591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
    Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
    Akizawa T; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.